Fight Colorectal Cancer launches its fifth annual United in Blue installation on the National Mall from March 1-14, 2026, featuring over 27,000 blue flags representing people under 50 projected to be diagnosed with colorectal cancer in 2030. The installation comes as new American Cancer Society research confirms colorectal cancer has become the deadliest cancer for Americans under 50, with mortality increasing in 2025.

Ahead of the March 6, 2026 FDA decision on Bristol Myers Squibb's Sotyktu (deucravacitinib) for psoriatic arthritis, a survey of 104 U.S. rheumatologists shows strong pre-launch awareness with one-third viewing it as a substantial advance. However, BMS ranks lowest among major pharmaceutical partners in rheumatology and is expected to capture roughly one-fifth of PsA patients through brand-to-brand share shifts rather than market expansion. The launch represents a critical opportunity for BMS to strengthen its standing in the specialty.

The American Kidney Fund (AKF) is launching its Kidney Month campaign on March 1, 2026, to raise awareness about kidney disease affecting 1 in 7 American adults. The campaign emphasizes early detection and prevention through the 'Kidneys Count' initiative and encourages people to pledge to discuss kidney health with their doctors. AKF will host Kidney Action Week (March 2-5) featuring expert sessions on kidney disease management and treatment options.

VivaVision Biotech, a developer of eye disease treatments, has submitted an IPO application to the Hong Kong Stock Exchange in a race against time to secure funding before cash reserves deplete. With only $5.2 million in cash as of September 2025 and quarterly burn rates of ~$6.3 million, the company must complete its IPO within months. Two core products have reached Phase Three trials, including a breakthrough therapy for eye inflammation, but the company faces intense competition in the dry eye disease market.

The global Advanced Drug Delivery Systems market is projected to grow from $299.6 billion in 2025 to $487.4 billion by 2030 at a CAGR of 10.2%. Growth is driven by increasing chronic disease prevalence, nanotechnology advances, and R&D investments. Oncology leads adoption, with North America dominating market share while Asia-Pacific shows the fastest growth. Key innovations include strategic partnerships in antibody-drug conjugates and AI-powered drug development optimization.

CVS Health announced it will add biosimilar medications Ospomyv and Stoboclo, along with generic teriparatide products, to its formularies starting April 1, 2026, replacing branded drugs from Amgen and Eli Lilly. The move aims to reduce prescription drug costs by more than 50% per prescription. CVS previously achieved $1.5 billion in gross savings by replacing AbbVie's Humira with biosimilars.

The global anti-obesity drugs market is estimated at US$22.52 billion in 2026 and is projected to grow at a CAGR of 24.2% to reach US$195.99 billion by 2036, driven by rising obesity rates, improved clinical efficacy of GLP-1 and multi-agonist therapies, and broader recognition of obesity as a chronic disease. However, US trade tariffs are adding cost pressures to pharmaceutical supply chains.

Amgen (AMGN) is trading near 52-week highs, up 8% in the latest session, driven by solid Q4 and full-year 2025 earnings with 10% revenue growth. The stock trades at a reasonable forward P/E of 15.6x despite delivering double-digit revenue growth, suggesting potential undervaluation. Wall Street analysts have raised price targets, with Goldman Sachs targeting $415 and RBC at $360. The breakout is supported by a diversified product portfolio, pipeline progress, and relative valuation advantage compared to mega-cap tech stocks.

The global oncology biosimilars market is projected to grow from $9.6 billion in 2025 to $17.5 billion by 2030, at a CAGR of 12.6%. Growth is driven by rising cancer incidence, expiring biologic patents, and cost-effective treatment demand. AI and machine learning are being leveraged to streamline clinical trials and accelerate market entry, with key opportunities in breast, lung, and blood cancer indications across emerging markets.

CytomX Therapeutics announced that management will participate in two upcoming conferences in February 2026: the Guggenheim Emerging Outlook Biotech Summit on February 11 in New York and World ADC London on February 25 in London. The clinical-stage biopharmaceutical company, focused on conditionally activated biologics for oncology, continues to advance its pipeline including varsetatug masetecan and CX-801.

The global targeted cancer therapy market is projected to grow from USD 90.89 billion in 2025 to USD 175.48 billion by 2035 at a CAGR of 6.80%. Growth is driven by antibody-drug conjugates (ADCs), KRAS inhibitors, bispecific antibodies, and regulatory productivity. Monoclonal antibodies capture 43% revenue share, lung cancer represents 32% of the market, and hospitals account for 58% of end-user share. North America dominates with 39% market share.

The article argues that the Magnificent 7 tech stocks' dominance is fading as AI benefits spread to other sectors. The author recommends rebalancing away from tech and investing in the Abrdn Life Sciences Investors (HQL) closed-end fund, which yields 11.6% and focuses on biopharma companies poised to benefit from AI optimization in drug development.